Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04094610 · ClinicalTrials.gov registry record · Phase 1
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
A Phase 1 study of Lymphoma and Metastatic Solid Tumors, sponsored by Turning Point Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 20
- Study locations
NCT04094610: Recruiting Phase 1 study of Lymphoma and Metastatic Solid Tumors, sponsored by Turning Point Therapeutics.
NCT04094610 is a Phase 1 study of Lymphoma and Metastatic Solid Tumors that is actively recruiting participants, run by Turning Point Therapeutics. The registered enrollment target is 75 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04094610, a Phase 1 study of Lymphoma and Metastatic Solid Tumors, is actively recruiting participants, sponsored by Turning Point Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.
Primary Outcome
Define the dose limiting toxicities (DLTs) (Phase 1)
Conditions Studied
Interventions
- DRUG Oral repotrectinib (TPX-0005)
Study Locations (20)
Texas
- The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center - Dallas
- Baylor College of Medicine - Houston
- Local Institution - 2104 - Houston
California
- Children's Hospital Los Angeles - Los Angeles
- University of California at Los Angeles - Los Angeles
Florida
- Local Institution - 2105 - Orlando
- Local Institution - 2120 - Orlando
Pennsylvania
- Local Institution - 2114 - Hershey
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research - Philadelphia
Colorado
- Children's Hospital Colorado - Anschutz Medical Campus - Aurora
Georgia
- Children's Healthcare of Atlanta - Egleston Hospital - Atlanta
Maine
- Maine Medical Center - Scarborough
Massachusetts
- Dana Farber Cancer Institute. - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-03-12 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 1 |
What NCT04094610 shows while recruiting
NCT04094610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (84% lower).
The record links to 4 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Oral repotrectinib (TPX-0005) is the first listed.
NCT04094610 names 20 study sites across 15 states, led by Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04094610 about?
NCT04094610 is a clinical study titled "A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations". Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor ki...
What is the current status of trial NCT04094610?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2020-03-12. Estimated completion is 2027-09-30.
What conditions does trial NCT04094610 study?
This clinical trial studies the following conditions: Lymphoma, Metastatic Solid Tumors, Locally Advanced Solid Tumors, Primary CNS Tumors.
What interventions are being tested in trial NCT04094610?
The interventions under investigation include: Oral repotrectinib (TPX-0005) (DRUG).
Who is sponsoring clinical trial NCT04094610?
This trial is sponsored by Turning Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04094610 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04094610's enrollment target sits among peer trials
75 110th of 299 higher than 188 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI